DuPont has strengthened its position in the bioprocessing market with the commercial launch of DuPont™ AmberChrom™ TQ1 chromatography resin, a specialized purification solution targeting the rapidly growing oligonucleotide and peptide therapeutics sector. The agarose-based anion exchange resin was unveiled at the TIDES USA conference, marking a significant expansion of the company's bioprocessing capabilities.
Enhanced Performance Characteristics Drive Market Differentiation
The AmberChrom TQ1 resin delivers measurable improvements over existing market alternatives, featuring increased loading capacity and higher throughput while requiring significantly less pressure during operation. These performance enhancements position the product as an optimal choice for high-resolution separations and polishing applications, particularly in the purification of closely-related impurities from target biomolecules.
"The introduction of DuPont™ AmberChrom™ TQ1 chromatography resin supports the accelerated development and commercialization of oligonucleotide and peptide therapeutics," said Shane Kendra, Global Bioprocessing Market Leader for DuPont Water Solutions. "This new anion exchange chromatography resin offers exceptional performance, setting a new standard in this product class and creating new opportunities in high growth therapy areas."
The resin's low-pressure build-up characteristics, combined with demonstrated high-yield and purity outcomes for both peptides and oligonucleotides in DMT-Off and DMT-On configurations, enable scalable applications from benchtop research to large-scale commercial manufacturing.
Comprehensive Application Validation Supports Market Entry
DuPont has published extensive internal application studies utilizing real-world drug feeds to validate the resin's performance characteristics. This documentation package is designed to facilitate product integration across all phases of drug development, from initial discovery through commercial production. The studies demonstrate the resin's effectiveness in biomolecule purifications and its ability to achieve high-purity fractions consistently.
Dr. Hadi Fares, a bioprocessing application scientist with DuPont, presented performance data at TIDES USA, showcasing how AmberChrom TQ1 complements existing resins within DuPont's bioprocessing portfolio. The presentation highlighted the resin's compatibility with established AmberChrom XT and CG chromatography resins for comprehensive oligonucleotide purification workflows.
Strategic Portfolio Integration Addresses Market Needs
The AmberChrom TQ1 launch represents DuPont's strategic response to increasing demand for specialized purification solutions in the oligonucleotide and peptide therapeutics market. The resin can function as a standalone solution or integrate with existing DuPont chromatography products to create comprehensive purification workflows.
"Further expansion of DuPont's bioprocessing portfolio reflects our commitment to providing a comprehensive one-stop shop for the purification and polishing of oligonucleotides and peptides," Kendra explained. "Our technical teams and scientists are continually collaborating with customers to design efficient bioprocessing solutions for every stage of the drug development journey."
The product's versatility extends to crude purification of peptide feeds in preparation for reverse phase chromatography, broadening its application scope across diverse therapeutic development programs.
Market Education and Technical Support Initiatives
DuPont has scheduled an educational webinar for June 19, 2025, focusing on AmberChrom TQ1's capabilities and its potential to enhance oligonucleotide and peptide purification processes. The session will address loading capacity optimization and purification efficacy improvements achievable through the new resin technology.
The company's 80-year heritage in adsorbents and ion exchange resins provides a foundation for supporting complex separations across small molecule synthetics, oligonucleotides, peptides, and diagnostic applications. This experience base enables DuPont to address sophisticated purification challenges that pharmaceutical companies encounter in developing treatments for various diseases.
The AmberChrom TQ1 launch underscores the growing importance of specialized bioprocessing technologies in advancing next-generation therapeutics, particularly as oligonucleotide and peptide-based treatments gain prominence in addressing previously intractable medical conditions.
